Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area

Radiologia Medica

Volumn 121, Issue 2, 2016, Pages 122-131

  Granata, Vincenza ^a   de Lutio di Castelguidone, Elisabetta ^a   Fusco, Roberta ^a   Catalano, Orlando ^a   Piccirillo, Mauro ^a   Palaia, Raffaele ^a   Izzo, Francesco ^a   Gallipoli, Adolfo D’Errico ^a   Petrillo, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Computed tomography; Contrast enhanced ultrasound; Hepatocellular carcinoma; Liver ablation; Magnetic resonance imaging; Response to treatment

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOXETIC ACID;

AGED; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ELECTROCHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; ELECTROCHEMOTHERAPY; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84955723007     PISSN: 00338362     EISSN: 18266983     Source Type: Journal    
DOI: 10.1007/s11547-015-0582-5     Document Type: Article

References (33)

1. Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022
2. European Association for the Study of the Liver*, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. Eur J Cancer 48:599–641
3. Curley SA, Izzo F, Ellis LM et al (2000) Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381–391
4. Curley SA, Marra P, Beaty K et al (2004) Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 239:450–458
5. Thomson KR, Cheung W, Ellis SJ et al (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22:611–621
6. Philips P, Hays D, Martin RC (2013) Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS ONE 8:e76260
7. Deodhar A, Dickfeld T, Single GW et al (2011) Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR 196:W330–W335
8. Appelbaum L, Ben-David E, Faroja M et al (2014) Irreversible electroporation ablation: creation of large-volume ablation zones in in vivo porcine liver with four-electrode arrays. Radiology 270:416–424
9. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214
10. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
11. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
12. Yang W, Yan K, Wu GX et al (2015) Radiofrequency ablation of hepatocellular carcinoma in difficult locations: strategies and long-term outcomes. World J Gastroenterol 21:1554–1566
13. Granata V, Petrillo M, Fusco R et al (2013) Surveillance of HCC patients after liver RFA: role of MRI with hepatospecific contrast versus three-phase CT scan. Experience of high volume oncologic institute. Gastroenterol Res Pract 2013:469097
14. Goldberg SN, Grassi CJ, Cardella JF et al (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 16:765–778
15. Appelbaum L, Ben-David E, Faroja M et al (2014) Irreversible electroporation ablation: creation of large-volume ablation zones in in vivo porcine liver with four-electrode arrays. Radiology 270:416–424
16. Ben-David E, Ahmed M, Faroja M et al (2013) Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties. Radiology 269:738–747
17. Deodhar A, Monette S, Single GW Jr et al (2011) Percutaneous irreversible electroporation lung ablation: preliminary results in a porcine model. Cardiovasc Intervent Radiol 34:1278–1287
18. Lee YJ, Lu DS, Osuagwu F et al (2013) Irreversible electroporation in porcine liver: acute computed tomography appearance of ablation zone with histopathologic correlation. J Comput Assist Tomogr 37:154–158
19. Guo Y, Zhang Y, Klein R et al (2010) Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res 70:1555–1563
20. Zhang Y, Guo Y, Ragin AB (2010) MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: preclinical feasibility studies in a rodent model. Radiology 256:424–432
21. Lencioni R, Izzo F, Crocetti L et al (2012) A prospective, multicenter phase II clinical trial using irreversible electroporation for the treatment of early stage HCC. J Vasc Interv Radiol 23:1114
22. Sugimoto K, Moriyasu F, Kobayashi Y et al (2015) Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. Jpn J Radiol [Epub ahead of print]. doi:10.1007/s11604-015-0442-1
23. Cheung W, Kavnoudias H, Roberts S et al (2013) Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 12:233–241
24. Lee EW, Wong D, Prikhodko SV et al (2012) Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol 23:107–113
25. Lencioni R, Crocetti L (2012) Local-regional treatment of hepatocellular carcinoma. Radiology 262:43–58
26. Bower M, Sherwood L, Li Y et al (2011) Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 104:22–28
27. Silk MT, Wimmer T, Lee KS et al (2014) Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 25:112–118
28. Granata V, Fusco R, Catalano O et al (2015) MRI findingsafter irreversible electroporation of hepatocellular carcinoma. AJR 204:1000–1007
29. Eisele RM, Schumacher G, Lopez-Hänninen E et al (2007) Role of B-mode ultrasound screening in detection of local tumor recurrence in the first year after radiofrequency ablation in the liver. Cancer Detect Prev 31:316–322
30. Khankan AA, Murakami T, Onishi H et al (2008) Hepatocellular carcinoma treated with radiofrequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 27:546–551
31. Paudyal B, Oriuchi N, Paudyal P et al (2007) Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 18:1469–1473
32. Ayuso C, Rimola J, García-Criado A (2012) Imaging of HCC. Abdom Imaging 37:215–230
33. Catalano O, Izzo F, Vallone P et al (2015) Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 56:133–142